January 4, 2024
VIA EMAIL AND EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jessica Dickerson, Esq.
Division of Corporation Finance
Re: IGC Pharma, Inc.
Registration Statement on Form S-3 (No. 333-276330)
Ladies and Gentlemen:
On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration Statement to 4:00 p.m., Eastern time, on Monday, January 8, 2024, or as soon as possible thereafter.
Please advise the undersigned of the effectiveness of the Registration Statement.
|
Very truly yours, |
|
|
/s/ Kenneth Schlesinger |
|
|
Kenneth Schlesinger |
cc: Mr. Ram Mukunda
Ms. Claudia Grimaldi
IGC Pharma, Inc.
10224 Falls Road
Potomac, MD 20854
January 4, 2024
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jessica Dickerson, Esq.
Division of Corporation Finance
Re: IGC Pharma, Inc.
Registration Statement on Form S-3 (No. 333-276330)
Ladies and Gentlemen:
IGC Pharma, Inc. hereby requests that the effectiveness of the above-referenced Registration Statement be accelerated so that it will become effective at 4:00 p.m., Eastern time, on Monday, January 8, 2024, or as soon as possible thereafter.
|
Very truly yours, |
||
|
IGC PHARMA, INC. |
||
|
By: |
/s/ Ram Mukunda |
|
|
Ram Mukunda |
||
|
Chief Executive Officer and President |
||